HOWL - Werewolf Therapeutics GAAP EPS of -$0.53 misses by $0.11 revenue of $4.15M
- Werewolf Therapeutics press release ( NASDAQ: HOWL ): Q2 GAAP EPS of -$0.53 misses by $0.11 .
- Revenue of $4.15M.
- As of June 30, 2022, cash and cash equivalents were $145.7 million, compared to $157.5 million as of December 31, 2021.
For further details see:
Werewolf Therapeutics GAAP EPS of -$0.53 misses by $0.11, revenue of $4.15M